Monoferric denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for monoferric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Monoferric as Duplicate Therapy

Monoferric (ferric derisomaltose) is an intravenous iron replacement agent. An Aetna duplicate-therapy denial means the plan determined that another iron therapy — most commonly oral iron supplementation or a different intravenous iron formulation already authorized — is already in use or on file and is considered therapeutically equivalent. Aetna may also raise this denial if a prior intravenous iron infusion was recently administered and the plan views repeat treatment within a defined window as duplicating an ongoing course of therapy.

## Why This Denial Is Appealable

Monoferric is not interchangeable with oral iron for patients who cannot tolerate or absorb oral formulations, and different intravenous iron products have distinct pharmacokinetic profiles that may affect dosing strategy and patient suitability. If your physician selected Monoferric because oral iron failed, was not tolerated, or is contraindicated for your condition, the clinical record should document that explicitly. If a different IV iron agent was previously used but was inadequate, your prescriber can document the outcome and the clinical rationale for transitioning to Monoferric specifically. The duplicate-therapy label does not apply when the prior therapy demonstrably failed or was inappropriate for your clinical situation.

## Federal Appeal Framework

• Internal appeal: File within Aetna's stated deadline (typically 180 days from the denial notice). Aetna must decide within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719 / ERISA §503): If the internal appeal is upheld, request independent external review within approximately four months of the final internal denial. An IRO will assess whether the duplicate-therapy classification is consistent with accepted clinical standards.
• Expedited review: If your condition creates clinical urgency (e.g., severe symptomatic anemia), request expedited review for a decision typically within 72 hours.

## Documentation to Gather

1. Diagnosis and iron-deficiency confirmation: Lab results confirming iron deficiency or iron-deficiency anemia and the underlying condition driving it (e.g., inflammatory bowel disease, chronic kidney disease, heart failure, post-surgical malabsorption). 2. Oral iron trial history: Documentation of any oral iron attempt — the agent, duration, and reason for failure (intolerance, malabsorption, inadequate response, contraindication). 3. Prior IV iron history (if applicable): Records of any previous IV iron infusions, including which agent was used, the response achieved, and the clinical rationale for choosing Monoferric now. 4. Prescriber letter: A medical-necessity letter from your treating physician explaining why Monoferric specifically — rather than an alternative — is the appropriate agent for your clinical situation, and why prior or concurrent therapies are not duplicative. 5. Relevant guideline reference: Your physician may reference the applicable guideline organization (e.g., KDIGO for CKD-related iron deficiency, applicable GI society guidelines for IBD) without needing to cite specific numbers.

## Criteria-Mapping Structure

Request Aetna's clinical policy for intravenous iron therapy. Map your case to each requirement:

| Policy Criterion | Your Clinical Evidence | Source | |---|---|---| | Iron deficiency confirmed | Lab results [date] showing iron studies | Lab report | | Oral iron not appropriate | Trial/failure/intolerance documented | Chart notes + med history | | Prior IV iron insufficient (if applicable) | Agent, outcome, and gap documented | Infusion records + notes | | Clinical rationale for Monoferric specifically | Prescriber letter paragraph | Letter [date] | | Underlying condition requiring IV route | Diagnosis + clinical summary | Office notes |

A complete record showing that no current or prior therapy is actually duplicating Monoferric's role should rebut this denial effectively.